Compugen Q3 net loss narrows 17% to USD 5.8 million; revenues more than double to USD 3.82 million
CGEN•Compugen’s third-quarter 2026 net loss narrowed 17% year over year to $5.8 million, while revenue more than doubled to $3.82 million. The company reported $117.5 million in cash and cash-related balances at September 30, with funding expected into 2029.
1. Quarterly results
Compugen’s third-quarter 2026 net loss narrowed 17% year over year to $5.8 million, and revenue more than doubled to $3.82 million. Cash and cash-related balances totaled $117.5 million at September 30, with funding expected into 2029.
2. Clinical milestones
MAIA-ovarian completed enrollment, and COM701 results are expected by the end of the first quarter of 2027. AstraZeneca’s Phase 3 ARTEMIDE-Biliary01 high-level results for rilvegostomig are anticipated in the second half of 2027.
